Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 21 | 2013 | 50 | 4.620 |
Why?
| | Anti-Bacterial Agents | 19 | 2017 | 206 | 4.320 |
Why?
| | Amphotericin B | 12 | 2013 | 19 | 2.310 |
Why?
| | Vancomycin | 6 | 2016 | 29 | 1.930 |
Why?
| | Neoplasms | 7 | 2017 | 96 | 1.850 |
Why?
| | Microbial Sensitivity Tests | 24 | 2017 | 124 | 1.600 |
Why?
| | Aspergillosis | 7 | 2011 | 10 | 1.570 |
Why?
| | Triazoles | 5 | 2012 | 13 | 1.280 |
Why?
| | Aqueous Humor | 6 | 2008 | 6 | 1.280 |
Why?
| | Vitreous Body | 6 | 2008 | 25 | 1.270 |
Why?
| | Gram-Positive Bacteria | 3 | 2015 | 11 | 1.180 |
Why?
| | Lung Diseases, Fungal | 5 | 2009 | 10 | 1.120 |
Why?
| | Aza Compounds | 5 | 2009 | 13 | 1.110 |
Why?
| | Quinolines | 5 | 2009 | 30 | 1.090 |
Why?
| | Echinocandins | 7 | 2011 | 19 | 1.050 |
Why?
| | Humans | 43 | 2017 | 7258 | 1.050 |
Why?
| | Aspergillus fumigatus | 5 | 2011 | 6 | 1.040 |
Why?
| | Candidiasis | 6 | 2009 | 20 | 1.010 |
Why?
| | Polymyxins | 3 | 2013 | 10 | 0.980 |
Why?
| | Acetamides | 3 | 2014 | 5 | 0.960 |
Why?
| | Oxazolidinones | 3 | 2014 | 4 | 0.960 |
Why?
| | Cephalosporins | 7 | 2017 | 18 | 0.930 |
Why?
| | Pyrimidines | 4 | 2011 | 28 | 0.920 |
Why?
| | Aminoglycosides | 4 | 2016 | 16 | 0.870 |
Why?
| | Peptides, Cyclic | 4 | 2005 | 11 | 0.820 |
Why?
| | Candida | 4 | 2009 | 27 | 0.800 |
Why?
| | Daptomycin | 2 | 2015 | 4 | 0.800 |
Why?
| | Drug Resistance, Bacterial | 4 | 2013 | 41 | 0.700 |
Why?
| | Disease Models, Animal | 8 | 2013 | 312 | 0.680 |
Why?
| | Linezolid | 4 | 2015 | 4 | 0.680 |
Why?
| | Polymyxin B | 2 | 2015 | 31 | 0.670 |
Why?
| | Acinetobacter baumannii | 3 | 2015 | 19 | 0.650 |
Why?
| | Escherichia coli | 3 | 2015 | 159 | 0.620 |
Why?
| | Rhizopus | 2 | 2011 | 2 | 0.610 |
Why?
| | Mucormycosis | 2 | 2011 | 3 | 0.610 |
Why?
| | Aspergillus | 3 | 2013 | 4 | 0.610 |
Why?
| | Mice | 12 | 2013 | 1116 | 0.590 |
Why?
| | Escherichia coli Infections | 2 | 2010 | 6 | 0.580 |
Why?
| | Female | 21 | 2013 | 4162 | 0.570 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2010 | 30 | 0.570 |
Why?
| | Middle Aged | 19 | 2013 | 1841 | 0.560 |
Why?
| | Neutropenia | 3 | 2013 | 7 | 0.560 |
Why?
| | Bacterial Infections | 2 | 2017 | 17 | 0.560 |
Why?
| | Aged | 16 | 2013 | 1145 | 0.560 |
Why?
| | Lung | 8 | 2010 | 88 | 0.530 |
Why?
| | Gram-Positive Bacterial Infections | 3 | 2014 | 11 | 0.510 |
Why?
| | Levofloxacin | 2 | 2015 | 11 | 0.500 |
Why?
| | Gram-Negative Bacteria | 1 | 2017 | 16 | 0.470 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 6 | 0.470 |
Why?
| | Staphylococcal Infections | 1 | 2016 | 13 | 0.470 |
Why?
| | Mycoses | 2 | 2012 | 7 | 0.450 |
Why?
| | Animals | 12 | 2013 | 3827 | 0.450 |
Why?
| | Deoxycholic Acid | 2 | 2006 | 5 | 0.440 |
Why?
| | Teicoplanin | 1 | 2015 | 1 | 0.440 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 2 | 0.440 |
Why?
| | Fluconazole | 3 | 2002 | 11 | 0.440 |
Why?
| | Adult | 16 | 2013 | 2487 | 0.430 |
Why?
| | Caprylates | 1 | 2015 | 4 | 0.430 |
Why?
| | Mice, Inbred BALB C | 6 | 2013 | 81 | 0.430 |
Why?
| | Gliotoxin | 2 | 2005 | 2 | 0.430 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 130 | 0.410 |
Why?
| | Lipids | 2 | 2012 | 45 | 0.390 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 70 | 0.380 |
Why?
| | Candida albicans | 2 | 2005 | 4 | 0.380 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 1 | 0.360 |
Why?
| | Chromatography, High Pressure Liquid | 8 | 2008 | 69 | 0.360 |
Why?
| | Serum | 2 | 2009 | 14 | 0.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 9 | 0.340 |
Why?
| | Itraconazole | 2 | 2002 | 3 | 0.330 |
Why?
| | Male | 14 | 2013 | 4565 | 0.330 |
Why?
| | Chromatography, Liquid | 2 | 2008 | 34 | 0.330 |
Why?
| | Aged, 80 and over | 6 | 2013 | 397 | 0.320 |
Why?
| | Drug Carriers | 3 | 2006 | 14 | 0.320 |
Why?
| | Pneumonia | 1 | 2011 | 13 | 0.320 |
Why?
| | Prospective Studies | 6 | 2012 | 249 | 0.310 |
Why?
| | Treatment Outcome | 5 | 2013 | 397 | 0.300 |
Why?
| | Quinolones | 1 | 2010 | 7 | 0.300 |
Why?
| | Liposomes | 2 | 2007 | 16 | 0.290 |
Why?
| | Pneumonia, Bacterial | 1 | 2010 | 14 | 0.290 |
Why?
| | Fungemia | 1 | 2009 | 6 | 0.290 |
Why?
| | Microbial Viability | 1 | 2009 | 10 | 0.290 |
Why?
| | Lipopeptides | 5 | 2011 | 13 | 0.290 |
Why?
| | Immunosuppressive Agents | 2 | 2006 | 13 | 0.280 |
Why?
| | Fluoroquinolones | 5 | 2009 | 19 | 0.280 |
Why?
| | Biological Availability | 5 | 2008 | 14 | 0.270 |
Why?
| | Models, Biological | 3 | 2006 | 301 | 0.270 |
Why?
| | Time Factors | 4 | 2016 | 709 | 0.270 |
Why?
| | Vitrectomy | 5 | 2008 | 6 | 0.270 |
Why?
| | Plasma | 1 | 2008 | 12 | 0.270 |
Why?
| | Collagen | 2 | 2005 | 26 | 0.260 |
Why?
| | Anti-Infective Agents | 1 | 2008 | 41 | 0.250 |
Why?
| | Gram-Negative Aerobic Bacteria | 1 | 2007 | 2 | 0.250 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2007 | 17 | 0.240 |
Why?
| | Immunologic Factors | 1 | 2006 | 3 | 0.240 |
Why?
| | Adrenal Cortex Hormones | 1 | 2006 | 7 | 0.240 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2006 | 2 | 0.240 |
Why?
| | Voriconazole | 4 | 2011 | 6 | 0.240 |
Why?
| | Cell Wall | 1 | 2005 | 7 | 0.220 |
Why?
| | Drug Resistance, Microbial | 1 | 2005 | 14 | 0.220 |
Why?
| | Calcineurin | 1 | 2005 | 42 | 0.220 |
Why?
| | Endophthalmitis | 1 | 2005 | 1 | 0.210 |
Why?
| | Gram-Positive Cocci | 1 | 2005 | 1 | 0.210 |
Why?
| | Catheterization, Central Venous | 1 | 2005 | 3 | 0.210 |
Why?
| | Biofilms | 1 | 2005 | 9 | 0.210 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 1 | 0.200 |
Why?
| | Meningitis, Fungal | 1 | 2004 | 1 | 0.200 |
Why?
| | Cornea | 1 | 2005 | 115 | 0.200 |
Why?
| | Colony Count, Microbial | 3 | 2009 | 29 | 0.190 |
Why?
| | Administration, Oral | 3 | 2012 | 66 | 0.190 |
Why?
| | Peptides | 1 | 2004 | 87 | 0.190 |
Why?
| | Catheterization | 1 | 2002 | 8 | 0.180 |
Why?
| | Half-Life | 4 | 2007 | 18 | 0.170 |
Why?
| | Infusions, Intravenous | 3 | 2012 | 38 | 0.170 |
Why?
| | Adolescent | 6 | 2013 | 1090 | 0.170 |
Why?
| | Drug Synergism | 2 | 2015 | 35 | 0.170 |
Why?
| | Drug Combinations | 3 | 2006 | 29 | 0.160 |
Why?
| | Administration, Topical | 3 | 2008 | 11 | 0.160 |
Why?
| | Survival Analysis | 2 | 2013 | 59 | 0.160 |
Why?
| | Total Lung Capacity | 1 | 2000 | 1 | 0.150 |
Why?
| | Pneumonectomy | 1 | 2000 | 2 | 0.150 |
Why?
| | Forced Expiratory Volume | 1 | 2000 | 6 | 0.150 |
Why?
| | Pulmonary Emphysema | 1 | 2000 | 3 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2005 | 270 | 0.150 |
Why?
| | Amikacin | 2 | 2010 | 7 | 0.140 |
Why?
| | Ofloxacin | 2 | 2010 | 13 | 0.140 |
Why?
| | Culture Media | 3 | 2005 | 30 | 0.140 |
Why?
| | Drug Incompatibility | 1 | 1998 | 1 | 0.130 |
Why?
| | Catheterization, Peripheral | 1 | 1998 | 5 | 0.130 |
Why?
| | Young Adult | 2 | 2013 | 690 | 0.130 |
Why?
| | Spinal Cord Injuries | 1 | 1997 | 17 | 0.120 |
Why?
| | Drug Antagonism | 2 | 2008 | 7 | 0.110 |
Why?
| | Area Under Curve | 2 | 2007 | 24 | 0.110 |
Why?
| | Klebsiella pneumoniae | 1 | 2015 | 14 | 0.110 |
Why?
| | Ophthalmic Solutions | 2 | 2005 | 11 | 0.110 |
Why?
| | Child | 3 | 2013 | 880 | 0.100 |
Why?
| | Child, Preschool | 2 | 2013 | 289 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 12 | 0.090 |
Why?
| | Administration, Intravenous | 1 | 2013 | 8 | 0.090 |
Why?
| | Bacteria | 1 | 2013 | 59 | 0.090 |
Why?
| | Tacrolimus | 1 | 2012 | 3 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 7 | 0.090 |
Why?
| | Leukemia | 1 | 2012 | 10 | 0.090 |
Why?
| | Prevalence | 1 | 2013 | 129 | 0.090 |
Why?
| | Lymphoma | 1 | 2012 | 12 | 0.090 |
Why?
| | In Vitro Techniques | 2 | 2005 | 224 | 0.090 |
Why?
| | Risk | 1 | 2012 | 62 | 0.090 |
Why?
| | Virulence | 1 | 2011 | 13 | 0.080 |
Why?
| | Drug Resistance, Fungal | 1 | 2011 | 6 | 0.080 |
Why?
| | Immunocompromised Host | 2 | 2004 | 8 | 0.080 |
Why?
| | Cancer Care Facilities | 1 | 2010 | 1 | 0.070 |
Why?
| | Random Allocation | 1 | 2010 | 33 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 58 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 109 | 0.070 |
Why?
| | Immunosuppression | 2 | 2002 | 6 | 0.070 |
Why?
| | DNA Gyrase | 1 | 2009 | 4 | 0.070 |
Why?
| | DNA Topoisomerase IV | 1 | 2009 | 4 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2004 | 42 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 24 | 0.070 |
Why?
| | Escherichia coli Proteins | 1 | 2009 | 35 | 0.070 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 73 | 0.070 |
Why?
| | Pharmacists | 1 | 1989 | 41 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2009 | 110 | 0.070 |
Why?
| | United States | 1 | 2010 | 441 | 0.070 |
Why?
| | Acinetobacter Infections | 1 | 2008 | 10 | 0.060 |
Why?
| | Mice, Inbred ICR | 1 | 2007 | 10 | 0.060 |
Why?
| | Injections, Intravenous | 1 | 2007 | 32 | 0.060 |
Why?
| | Cefotaxime | 1 | 1987 | 1 | 0.060 |
Why?
| | Bronchi | 1 | 1987 | 12 | 0.060 |
Why?
| | Hyphae | 1 | 2006 | 1 | 0.060 |
Why?
| | Survival | 1 | 2006 | 4 | 0.060 |
Why?
| | Neutrophils | 1 | 2006 | 58 | 0.060 |
Why?
| | Tablets | 1 | 2006 | 1 | 0.060 |
Why?
| | DNA, Fungal | 1 | 2006 | 6 | 0.060 |
Why?
| | Nortriptyline | 1 | 1986 | 1 | 0.060 |
Why?
| | Serum Albumin | 1 | 2005 | 11 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2005 | 6 | 0.050 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 2005 | 5 | 0.050 |
Why?
| | Biodegradation, Environmental | 1 | 2005 | 14 | 0.050 |
Why?
| | Species Specificity | 1 | 2005 | 116 | 0.050 |
Why?
| | Infusions, Parenteral | 1 | 2005 | 10 | 0.050 |
Why?
| | Subcutaneous Tissue | 1 | 2005 | 3 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2005 | 17 | 0.050 |
Why?
| | Phosphatidylglycerols | 1 | 2005 | 3 | 0.050 |
Why?
| | Phosphatidylcholines | 1 | 2005 | 10 | 0.050 |
Why?
| | Treatment Failure | 1 | 2005 | 22 | 0.050 |
Why?
| | Depressive Disorder | 1 | 1986 | 54 | 0.050 |
Why?
| | Enterococcus faecium | 1 | 2005 | 1 | 0.050 |
Why?
| | Staphylococcus epidermidis | 1 | 2005 | 4 | 0.050 |
Why?
| | Reference Values | 1 | 2005 | 149 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2005 | 23 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 25 | 0.050 |
Why?
| | Injections, Intraperitoneal | 1 | 2004 | 12 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2004 | 13 | 0.050 |
Why?
| | Chronic Disease | 1 | 2004 | 72 | 0.050 |
Why?
| | Fungi | 1 | 2004 | 7 | 0.050 |
Why?
| | Osmolar Concentration | 1 | 2004 | 27 | 0.050 |
Why?
| | Preoperative Care | 1 | 2004 | 17 | 0.050 |
Why?
| | Biological Transport | 1 | 2004 | 81 | 0.050 |
Why?
| | Cortisone | 1 | 2002 | 4 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2002 | 8 | 0.040 |
Why?
| | Chemoprevention | 1 | 2002 | 2 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 2002 | 60 | 0.040 |
Why?
| | Smoking | 1 | 1986 | 303 | 0.040 |
Why?
| | Radiography | 1 | 2000 | 27 | 0.040 |
Why?
| | Drug Interactions | 1 | 2000 | 56 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2000 | 61 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2000 | 166 | 0.040 |
Why?
| | Cohort Studies | 1 | 2000 | 175 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2000 | 340 | 0.030 |
Why?
| | Aminophylline | 1 | 1998 | 1 | 0.030 |
Why?
| | Ampicillin | 1 | 1998 | 2 | 0.030 |
Why?
| | Sodium Bicarbonate | 1 | 1998 | 3 | 0.030 |
Why?
| | Infusion Pumps, Implantable | 1 | 1998 | 3 | 0.030 |
Why?
| | Ondansetron | 1 | 1998 | 4 | 0.030 |
Why?
| | Fluorouracil | 1 | 1998 | 8 | 0.030 |
Why?
| | Drug Stability | 1 | 1998 | 20 | 0.030 |
Why?
| | Blood Proteins | 1 | 1998 | 23 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1998 | 76 | 0.030 |
Why?
| | Creatinine | 1 | 1997 | 17 | 0.030 |
Why?
| | Kidney Diseases | 1 | 1976 | 19 | 0.030 |
Why?
| | Mucorales | 1 | 1995 | 1 | 0.030 |
Why?
| | Fusarium | 1 | 1995 | 4 | 0.030 |
Why?
| | Opportunistic Infections | 1 | 1995 | 2 | 0.030 |
Why?
| | Communicable Diseases | 1 | 1989 | 13 | 0.020 |
Why?
| | Bronchoscopy | 1 | 1987 | 3 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1987 | 56 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 239 | 0.010 |
Why?
| | Penicillins | 1 | 1981 | 3 | 0.010 |
Why?
| | Tetracyclines | 1 | 1981 | 2 | 0.010 |
Why?
| | Meningitis | 1 | 1981 | 2 | 0.010 |
Why?
| | Infection | 1 | 1981 | 6 | 0.010 |
Why?
| | Permeability | 1 | 1981 | 21 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1981 | 9 | 0.010 |
Why?
| | Sulfonamides | 1 | 1981 | 19 | 0.010 |
Why?
| | Brain Diseases | 1 | 1981 | 18 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1981 | 113 | 0.010 |
Why?
| | Infant | 1 | 1981 | 151 | 0.010 |
Why?
| | Age Factors | 1 | 1976 | 224 | 0.010 |
Why?
|
|
Prince's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|